The long-term risks of Wegovy: an honest look at the evidence

You've been on Wegovy a while — and now you're reading the small print

It usually happens around the three- or six-month mark. The early nausea has settled, the pen routine is second nature, and then a news headline or a comment from a friend makes you stop and think: what does long-term use of this medicine actually do? That mix of curiosity and low-level unease is one our prescribers hear about regularly. It's a reasonable place to land.

The honest answer is that semaglutide has been studied more thoroughly than most weight-management medicines, and the STEP 1 trial published in the New England Journal of Medicine followed participants for 68 weeks at the 2.4mg maintenance dose, a reasonably long window for a clinical trial. Beyond that, cardiovascular outcome trials have tracked patients with semaglutide for several years. The overall pattern that emerges is one of a medicine with a manageable side-effect profile for most people, alongside a defined set of rarer risks that are genuinely important to know about. Understanding those risks doesn't mean stopping treatment; it means knowing what to watch for.

The side-effect profile of Wegovy across longer treatment periods is led by gastrointestinal symptoms: nausea, loose stools, constipation, indigestion and slower gastric emptying. These are well-characterised and, for most people, are most disruptive in the first four to eight weeks or after a dose step. They rarely disappear entirely for everyone, but the severity typically falls over time.

Risks that warrant more than a passing mention

Several risks associated with ongoing GLP-1 treatment require a little more weight than the usual nausea disclaimer. Gallbladder problems (including gallstones and cholecystitis) are more frequently reported in people on semaglutide than in placebo groups across trials. Rapid weight loss itself (through any method) increases gallstone risk, so the medicine and the effect it produces both play a role. If you develop upper-right abdominal pain, particularly after eating, that's worth raising with a clinician promptly.

Pancreatitis is rarer but more serious. In January 2026, the MHRA issued a formal Drug Safety Update drawing attention to acute pancreatitis as a known infrequent risk across GLP-1 receptor agonists. The key symptom pattern is severe, persistent stomach pain that may spread to the back, sometimes with vomiting. That warrants emergency assessment, not a wait-and-see approach. The full update is available through the MHRA Drug Safety Update index for anyone who wants to read the clinical language directly.

Heart rate: some people on semaglutide notice a modest increase in resting heart rate. In most cases this is clinically unremarkable, but it's monitored in trials and worth mentioning to your prescriber if you notice a persistent change. Kidney function can also be affected indirectly, severe dehydration from prolonged vomiting or diarrhoea places strain on the kidneys, which is one reason managing GI symptoms actively, rather than pushing through, matters. You can read a fuller account of how safe Wegovy is over the long term across the evidence base on a dedicated page.

When to get medical help, and what counts as urgent

Some symptoms during Wegovy treatment need same-day or emergency attention. The list isn't long, but it matters. Severe, persistent abdominal pain that reaches your back, possible pancreatitis, call 999 or go to A&E. Signs of a serious allergic reaction: swelling of the face, throat or tongue, difficulty breathing, a spreading rash. Gallbladder pain as described above: same-day GP contact at minimum. Significant dehydration from vomiting or diarrhoea that you cannot manage at home, your GP or 111.

Symptoms that are uncomfortable but not emergencies (persistent nausea, constipation, reflux, fatigue, headache) are worth logging and discussing at your next clinical review. They often respond to practical adjustments in how and when you eat, and your prescriber can advise. The NHS medicines page for semaglutide sets out this information clearly and is worth bookmarking.

If you experience something unexpected and aren't sure whether it's related to treatment, reporting it via the Yellow Card scheme helps the MHRA build a better long-term picture of these medicines in real-world use. You don't need a confirmed link to report, a suspicion is enough. Our prescribers are also available for aftercare support seven days a week if questions come up between reviews. You can reach the team through the contact page.

What longer-term use means in practice, and who decides

NICE's guidance on semaglutide for weight management (TA875) recommends treatment for a maximum of two years within a specialist service. Private prescribing follows the licensed indication and the prescriber's clinical judgement, which takes your individual history, response and risks specific to Wegovy into account at every repeat. There is no automatic renewal at nume: each repeat order is reviewed by a real clinician, which means the question of long-term suitability is being actively considered on your behalf rather than rubber-stamped.

The long-term side effects of Wegovy are a live area of research, and the evidence base will continue to grow as more people use these medicines for longer periods. What is clear now is that the risks are manageable for most people with appropriate oversight, that a few specific warning signs need prompt action, and that ongoing clinical review (not just a one-off prescription) is the right frame for extended treatment, particularly given what we know about the side effects that can emerge with prolonged use. If you'd like to talk through your individual situation, our prescribers discuss suitability and any concerns about side effects as part of the consultation.